Angiogenic and antiangiogenic gene therapy.

Abstract:

:Gene therapy is thought to be a promising method for the treatment of various diseases. One gene therapy strategy involves the manipulations on a process of formation of new vessels, commonly defined as angiogenesis. Angiogenic and antiangiogenic gene therapy is a new therapeutic approach to the treatment of cardiovascular and cancer patients, respectively. So far, preclinical and clinical studies are successfully focused mainly on the treatment of coronary artery and peripheral artery diseases. Plasmid vectors are often used in preparations in angiogenic gene therapy trials. The naked plasmid DNA effectively transfects the skeletal muscles or heart and successfully expresses angiogenic genes that are the result of new vessel formation and the improvement of the clinical state of patients. The clinical preliminary data, although very encouraging, need to be well discussed and further study surely continued. It is really possible that further development of molecular biology methods and advances in gene delivery systems will cause therapeutic angiogenesis as well as antiangiogenic methods to become a supplemental or alternative option to the conventional methods of treatment of angiogenic diseases.

journal_name

Gene Ther

journal_title

Gene therapy

authors

Malecki M,Kolsut P,Proczka R

doi

10.1038/sj.gt.3302621

subject

Has Abstract

pub_date

2005-10-01 00:00:00

pages

S159-69

eissn

0969-7128

issn

1476-5462

pii

3302621

journal_volume

12 Suppl 1

pub_type

杂志文章,评审
  • Beta defensin-3 engineered epidermis shows highly protective effect for bacterial infection.

    abstract::Defensins are small cationic proteins that harbor broad-spectrum microbicidal activity against bacteria, fungi and viruses. This study examines the effects on pathogens of the epidermis engineered to express human beta-defensin 3 (HBD3) to combat bacterial infections. First, we examined the localization of HBD3 in the...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3302472

    authors: Sawamura D,Goto M,Shibaki A,Akiyama M,McMillan JR,Abiko Y,Shimizu H

    更新日期:2005-05-01 00:00:00

  • Evidence for localization of biologically active recombinant retroviral vector to lymph nodes in mice injected intramuscularly.

    abstract::We have developed a novel gene transfer drug, HIV-IT(V), for the treatment of HIV infection in humans. HIV-IT(V) is a retroviral vector encoding the HIV-1 IIIB env and rev genes and a neomycin resistance marker gene (neor). We have recently reported that HIV-IT(V) administered intramuscularly to male mice localizes pr...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:

    authors: Kamantigue E,Edwards W 3rd,Chada S,Brumm D,Austin M,Irwin M,Mento S,Kowal K,Sajjadi N

    更新日期:1996-02-01 00:00:00

  • Gene therapy progress and prospects: bringing gene therapy into medical practice: the evolution of international ethics and the regulatory environment.

    abstract::The concept and application of ethical principles in the context of medical research is changing rapidly. This is especially true for fast moving fields such as gene therapy, a relatively new but rapidly maturing field offering opportunities to influence health at a fundamental level, which may become a cornerstone of...

    journal_title:Gene therapy

    pub_type: 杂志文章,评审

    doi:10.1038/sj.gt.3302354

    authors: Spink J,Geddes D

    更新日期:2004-11-01 00:00:00

  • Rat sodium iodide symporter allows using lower dose of 131I for cancer therapy.

    abstract::Efficient gene delivery is a critical obstacle for gene therapy that must be overcome. Until current limits of gene delivery technology are solved, identification of systems with bystander effects is highly desirable. As an anticancer agent, radioactive iodine (131)I has minimal toxicity. The physical characteristics ...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3302758

    authors: Mitrofanova E,Unfer R,Vahanian N,Link C

    更新日期:2006-07-01 00:00:00

  • Adenovirus targeting to HLA-A1/MAGE-A1-positive tumor cells by fusing a single-chain T-cell receptor with minor capsid protein IX.

    abstract::Adenovirus vectors have great potential in cancer gene therapy. Targeting of cancer-testis (CT) antigens, which are specifically presented at the surface of tumor cells by human leukocyte antigen (HLA) class I molecules, is an attractive option. In this study, a single-chain T-cell receptor (scTCR) directed against th...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2008.26

    authors: de Vrij J,Uil TG,van den Hengel SK,Cramer SJ,Koppers-Lalic D,Verweij MC,Wiertz EJ,Vellinga J,Willemsen RA,Hoeben RC

    更新日期:2008-07-01 00:00:00

  • Folate receptor mediated DNA delivery into tumor cells: potosomal disruption results in enhanced gene expression.

    abstract::We have used a particular folate receptor, which is overexpressed in tumor cells, for targeted DNA delivery into these cell types. This folate receptor internalizes folate through caveolae by a process named potocytosis, which is distinct from endocytosis, through clathrin-coated pits. When folate conjugated to poly-L...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:

    authors: Gottschalk S,Cristiano RJ,Smith LC,Woo SL

    更新日期:1994-05-01 00:00:00

  • DsAAV8-mediated expression of glucagon-like peptide-1 in pancreatic beta-cells ameliorates streptozotocin-induced diabetes.

    abstract::Glucagon-like peptide-1 (GLP-1) is an incretin hormone that performs a wide array of well-characterized antidiabetic actions, including stimulation of glucose-dependent insulin secretion, upregulation of insulin gene expression and improvements in beta-cell survival. GLP-1-receptor agonists have been developed for tre...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2009.143

    authors: Riedel MJ,Gaddy DF,Asadi A,Robbins PD,Kieffer TJ

    更新日期:2010-02-01 00:00:00

  • Ex vivo gene therapy in autologous bone marrow stromal stem cells for tissue-engineered maxillofacial bone regeneration.

    abstract::This study examines the clinical relevance of tissue engineering integrating gene therapy and polymer science to bone regeneration. Bilateral maxillary defects (3 x 1.2 cm(2)) in 20 miniature swine were bridged with a bioresorbable internal splint. Constructs were created using ex vivo adenovirus bone morphogenetic pr...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3302106

    authors: Chang SC,Chuang HL,Chen YR,Chen JK,Chung HY,Lu YL,Lin HY,Tai CL,Lou J

    更新日期:2003-11-01 00:00:00

  • Correction/mutation of acid alpha-D-glucosidase gene by modified single-stranded oligonucleotides: in vitro and in vivo studies.

    abstract::Deficiency in acid alpha-D-glucosidase results in Pompe's disease. Modified single-stranded oligonucleotide (ODN) was designed to correct the acid alpha-D-glucosidase gene with a C1935 --> A (Asp --> Glu) point mutation which causes a complete loss of enzymatic activity for glycogen digestion in the lysosome. The ODN ...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3302096

    authors: Lu IL,Lin CY,Lin SB,Chen ST,Yeh LY,Yang FY,Au LC

    更新日期:2003-10-01 00:00:00

  • Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-gamma receptor/IgG1 fusion protein.

    abstract::We report on long-term delivery of an interferon-gamma (IFN gamma) inhibitory protein by intramuscular (i.m.) gene therapy. IFN gamma is a cytokine that plays an important role in many inflammatory disorders, including autoimmune insulin-dependent diabetes mellitus (IDDM) in NOD mice and (in various strains) multiple ...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3300879

    authors: Prud'homme GJ,Chang Y

    更新日期:1999-05-01 00:00:00

  • An adenoviral vector-based mucosal vaccine is effective in protection against botulism.

    abstract::A replication-incompetent adenoviral vector encoding the heavy chain C-fragment (H(C)50) of botulinum neurotoxin type C (BoNT/C) was evaluated as a mucosal vaccine against botulism in a mouse model. Single intranasal inoculation of the adenoviral vector elicited a high level of H(C)50-specific IgG, IgG1 and IgG2a in s...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2008.181

    authors: Xu Q,Pichichero ME,Simpson LL,Elias M,Smith LA,Zeng M

    更新日期:2009-03-01 00:00:00

  • Lipofection of cultured mouse muscle cells: a direct comparison of Lipofectamine and DOSPER.

    abstract::Cationic lipid-DNA complexes (lipoplexes) have been widely used as gene transfer vectors which avoid the adverse immunogenicity and potential for viraemia of viral vectors. With the long-term aim of gene transfer into skeletal muscle in vivo, we describe a direct in vitro comparison of two commercially available catio...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3300604

    authors: Dodds E,Dunckley MG,Naujoks K,Michaelis U,Dickson G

    更新日期:1998-04-01 00:00:00

  • Tumor cells cotransduced with B7.1 and gamma-IFN induce effective rejection of established parental tumor.

    abstract::Genetic modification of tumor cells with the gene for the B7.1 or with the genes for cytokines results in increased tumor cell immunogenicity. In the work reported here, immunization of naive animals with either B7.1 or gamma-IFN gene-modified MCA106 tumor cells effectively protects the host from subsequent challenge ...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3300820

    authors: Yang S,Vervaert CE,Seigler HF,Darrow TL

    更新日期:1999-02-01 00:00:00

  • Insulin expressed from endogenously active glucose-responsive EGR1 promoter in bone marrow mesenchymal stromal cells as diabetes therapy.

    abstract::Advances in islet transplantation have encouraged efforts to create alternative insulin-secreting cells that overcome limitations associated with current therapies. We have recently demonstrated durable correction of murine and porcine diabetes by syngeneic and autologous implantation, respectively, of primary hepatoc...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2010.12

    authors: Chen NK,Tan SY,Udolph G,Kon OL

    更新日期:2010-05-01 00:00:00

  • Effects of dose, intervention time, and radionuclide on sodium iodide symporter (NIS)-targeted radionuclide therapy.

    abstract::The sodium iodide symporter (NIS) mediates iodide uptake into thyrocytes and is the molecular basis of thyroid radioiodine therapy. We previously have shown that NIS gene transfer into the F98 rat gliomas facilitated tumor imaging and increased survival by radioiodine. In this study, we show that: (1) the therapeutic ...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3302147

    authors: Shen DH,Marsee DK,Schaap J,Yang W,Cho JY,Hinkle G,Nagaraja HN,Kloos RT,Barth RF,Jhiang SM

    更新日期:2004-01-01 00:00:00

  • Effect of sustained PDGF nonviral gene delivery on repair of tooth-supporting bone defects.

    abstract::Recombinant human platelet-derived growth factor-BB (rhPDGF-BB) promotes soft tissue and bone healing, and is Food and Drug Administration-approved for treatment of diabetic ulcers and periodontal defects. The short half-life of topical rhPDGF-BB protein application necessitates bolus, high-dose delivery. Gene therapy...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2016.73

    authors: Plonka AB,Khorsand B,Yu N,Sugai JV,Salem AK,Giannobile WV,Elangovan S

    更新日期:2017-01-01 00:00:00

  • Disease-causing allele-specific silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia ossificans progressiva.

    abstract::Fibrodysplasia ossificans progressiva (FOP) is an autosomal dominant congenital disorder characterized by progressive heterotopic bone formation. Currently, no definitive treatment exists for FOP. The activin receptor type IA / activin-like kinase 2 (ACVR1/ALK2) gene has been identified as the responsible gene for FOP...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2011.193

    authors: Takahashi M,Katagiri T,Furuya H,Hohjoh H

    更新日期:2012-07-01 00:00:00

  • Transcriptionally active drugs improve adenovirus vector performance in vitro and in vivo.

    abstract::Cytomegalovirus (CMV) promoter is often present in recombinant adenovirus vectors (AdVs) suitable for gene therapy, ensuring high levels of transgene production in a wide range of hosts. Despite this characteristic, the presence of the AdV genome in target cells and tissues typically lasts longer than transgene produc...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301296

    authors: Gaetano C,Catalano A,Palumbo R,Illi B,Orlando G,Ventoruzzo G,Serino F,Capogrossi MC

    更新日期:2000-10-01 00:00:00

  • A comparison of gene repair strategies in cell culture using a lacZ reporter system.

    abstract::Synthetic oligonucleotides and DNA fragments of less than 1 kilobase (kb) have been shown to cause site-specific genetic alterations in mammalian cells in culture and in vivo. We have used a lacZ reporter gene system to compare the efficiency of episomal and chromosomal gene repair in human embryonic kidney epithelial...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3302049

    authors: Nickerson HD,Colledge WH

    更新日期:2003-09-01 00:00:00

  • Widespread transduction of astrocytes and neurons in the mouse central nervous system after systemic delivery of a self-complementary AAV-PHP.B vector.

    abstract::Until recently, adeno-associated virus 9 (AAV9) was considered the AAV serotype most effective in crossing the blood-brain barrier (BBB) and transducing cells of the central nervous system (CNS), following systemic injection. However, a newly engineered capsid, AAV-PHP.B, is reported to cross the BBB at even higher ef...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/s41434-018-0005-z

    authors: Rincon MY,de Vin F,Duqué SI,Fripont S,Castaldo SA,Bouhuijzen-Wenger J,Holt MG

    更新日期:2018-04-01 00:00:00

  • Systemic administration of naked plasmid encoding hepatocyte growth factor ameliorates chronic renal fibrosis in mice.

    abstract::The progression of chronic renal diseases is considered as an irreversible process that eventually leads to end-stage renal failure characterized by extensive tissue fibrosis. At present, chronic renal fibrosis is incurable and the incidence of affected patients is on the rise worldwide. In this study, we demonstrate ...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301545

    authors: Yang J,Dai C,Liu Y

    更新日期:2001-10-01 00:00:00

  • Novel GP64 envelope variants for improved delivery to human airway epithelial cells.

    abstract::Lentiviral vectors pseudotyped with the baculovirus envelope protein GP64 transduce primary cultures of human airway epithelia (HAE) at their apical surface. Our goal in this study was to harness a directed evolution approach to develop a novel envelope glycoprotein with increased transduction properties for HAE. Usin...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2017.78

    authors: Sinn PL,Hwang BY,Li N,Ortiz JLS,Shirazi E,Parekh KR,Cooney AL,Schaffer DV,McCray PB Jr

    更新日期:2017-10-01 00:00:00

  • Differentiation-specific enhancer activity in transduced keratinocytes: a model for epidermal gene therapy.

    abstract::HaCaT cells, a spontaneously immortalised, nontumorigenic keratinocyte line, were used as a more amenable model than primary keratinocytes for ex vivo-mediated gene transfer. These cells were transduced with retroviral vectors containing the factor IX cDNA under the control of a cytomegaloviral (CMV) promoter/enhancer...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3300591

    authors: Page SM,Brownlee GG

    更新日期:1998-03-01 00:00:00

  • Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins.

    abstract::Catheter-based percutaneous transluminal gene delivery (PTGD) into the coronary artery still falls behind the expectations of an efficient myocardial gene delivery system. In this study gene delivery was applied by selective pressure-regulated retroinfusion through the coronary veins to prolong adhesion of replication...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301079

    authors: Boekstegers P,von Degenfeld G,Giehrl W,Heinrich D,Hullin R,Kupatt C,Steinbeck G,Baretton G,Middeler G,Katus H,Franz WM

    更新日期:2000-02-01 00:00:00

  • Stable and monodisperse lipoplex formulations for gene delivery.

    abstract::A stable single vial lipoplex formulation has been developed that can be stored frozen without losing either biological activity or physical stability. This formulation was identified by systematically controlling several formulation variables and without introducing either stabilizers or surfactants. Analytical assay...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3300707

    authors: Zelphati O,Nguyen C,Ferrari M,Felgner J,Tsai Y,Felgner PL

    更新日期:1998-09-01 00:00:00

  • The clinical landscape for SMA in a new therapeutic era.

    abstract::Despite significant advances in basic research, the treatment of degenerative diseases of the nervous system remains one of the greatest challenges for translational medicine. The childhood onset motor neuron disorder spinal muscular atrophy (SMA) has been viewed as one of the more tractable targets for molecular ther...

    journal_title:Gene therapy

    pub_type: 杂志文章,评审

    doi:10.1038/gt.2017.52

    authors: Talbot K,Tizzano EF

    更新日期:2017-09-01 00:00:00

  • MuLV-based vectors pseudotyped with truncated HIV glycoproteins mediate specific gene transfer in CD4+ peripheral blood lymphocytes.

    abstract::Human immunodeficiency virus (HIV) infection ultimately leads to the destruction of the CD4+ lymphocyte subset and the onset of AIDS. In recent years, several gene therapy procedures making use of retroviral vectors that selectively target HIV susceptible cells have been proposed in order to interfere with HIV product...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3300646

    authors: Lodge R,Subbramanian RA,Forget J,Lemay G,Cohen EA

    更新日期:1998-05-01 00:00:00

  • Prolonged organ retention and safety of plasmid DNA administered in polyethylenimine complexes.

    abstract::Polyethylenimine (PEI) has been studied as an efficient nonviral gene transfer vector. Here, we report the biodistribution fates and safety of plasmid DNA intravenously administered in PEI complexes. Using pCMVbeta as a model gene, the biodistribution of plasmid DNA was measured by quantitative polymerase chain reacti...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301516

    authors: Oh YK,Kim JP,Yoon H,Kim JM,Yang JS,Kim CK

    更新日期:2001-10-01 00:00:00

  • Ocular gene delivery using lentiviral vectors.

    abstract::Substantial advances in our understanding of lentivirus lifecycles and their various constituent proteins have permitted the bioengineering of lentiviral vectors now considered safe enough for clinical trials for both lethal and non-lethal diseases. They possess distinct properties that make them particularly suitable...

    journal_title:Gene therapy

    pub_type: 杂志文章,评审

    doi:10.1038/gt.2011.153

    authors: Balaggan KS,Ali RR

    更新日期:2012-02-01 00:00:00

  • Chitosan-plasmid nanoparticle formulations for IM and SC delivery of recombinant FGF-2 and PDGF-BB or generation of antibodies.

    abstract::Growth factor therapy is an emerging treatment modality that enhances tissue vascularization, promotes healing and regeneration and can treat a variety of inflammatory diseases. Both recombinant human growth factor proteins and their gene therapy are in human clinical trials to heal chronic wounds. As platelet-derived...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2009.60

    authors: Jean M,Smaoui F,Lavertu M,Méthot S,Bouhdoud L,Buschmann MD,Merzouki A

    更新日期:2009-09-01 00:00:00